ENTX

Entera Bio Ltd

3.19

Nov 10 • 9:49 AM ET -0.06 (-1.85%)

Healthcare Biotechnology Israel Small NASD

Peers: RANI MBX ASND VKTX OPK SPRY AQST LPCN NVO AMGN

Index	-
Market Cap	555.50M
Enterprise Value	283.48M
Income	-29.43M
Sales	0.00M
Book/sh	1.58
Cash/sh	1.56
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	22
IPO	Jun 28, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.02
P/C	2.04
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	128.41
Current Ratio	128.41
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.39
EPS next Y	-0.39
EPS next Q	-0.15
EPS this Y	-83.00%
EPS next Y	15.85%
EPS next 5Y	-16.72%
EPS past 3/5Y	18.28% 16.47%
Sales past 3/5Y	-32.07% -35.11%
EPS Y/Y TTM	-59.89%
Sales Y/Y TTM	-100.00%
EPS Q/Q	-58.09%
Sales Q/Q	-
Earnings	Nov 06 AMC
EPS/Sales Surpr.	-69.23% -

Insider Own	20.20%
Insider Trans	0.00%
Inst Own	18.18%
Inst Trans	8.61%
ROA	-19.99%
ROE	-20.33%
ROIC	-10.72%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	6.23%
SMA50	10.58%
SMA200	62.71%
Trades

Shs Outstand	173.92M
Shs Float	138.80M
Short Float	4.00%
Short Ratio	11.91
Short Interest	5.55M
52W High	4.20 -24.05%
52W Low	0.91 250.55%
Volatility	7.52% 8.09%
ATR (14)	0.21
RSI (14)	58.75
Beta	1.46
Rel Volume	0.35
Avg Volume	465.73K
Volume	15,908

Perf Week	4.59%
Perf Month	20.38%
Perf Quarter	13.93%
Perf Half Y	155.20%
Perf YTD	64.43%
Perf Year	6.33%
Perf 3Y	355.71%
Perf 5Y	-15.83%
Perf 10Y	-
Recom	1.00
Target Price	10.00
Prev Close	3.25
Price	3.19
Change %	-1.85%

Consensus

Strong Buy

Avg. Price Target

$10.00

Implied Upside

+213.5%

Analysts4incl. previous ratings

Rating Distribution4 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 25, 2026	Initiated	GGuggenheim	Buy	$11	+244.8%
Sep 22, 2026	Initiated	CCantor Fitzgerald	Overweight
Sep 18, 2026	Initiated	LLeerink Partners	Outperform	$9	+182.1%
Mar 22, 2021	Initiated	AAegis Capital	Buy	$12	+276.2%

Oct-26-26 10:57AM	Gilead's Latest Deal Shows Big Pharma's Appetite for Oral Peptides. Which Stocks Are Worth Watching? (FinanceWire)
Oct-07-26 09:48AM	Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX) (FinanceWire)
Sep-23-26 08:30AM	Entera Bio Receives New Overweight Rating From Cantor Fitzgerald (NASDAQ: ENTX) (FinanceWire) -5.70%
Sep-18-26 08:11AM	Entera Receives $9 Price Target and New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX) (FinanceWire)
Aug-31-26 08:55AM	Entera is on the Cusp of the Trial That Could Unlock America's Osteoporosis Drug Market (NASDAQ: ENTX) (FinanceWire)
07:02AM	Loading…
Aug-10-26 07:02AM	Entera Bio shares slip as Q2 loss comes in wider than expected (InvestorsHub) +5.92%
Jul-30-26 09:00AM	Why the World's Leading Healthcare Funds All Wanted a Piece of Entera Bio (NASDAQ: ENTX) (FinanceWire)
Jul-29-26 03:00PM	Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE (PR Newswire) -7.98%
Jul-15-26 08:49AM	After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story? (FinanceWire) +9.88%
Jul-08-26 09:16AM	America's Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX) (FinanceWire)
Jun-22-26 02:29PM	ENTX Stock On Track For Best Day In Over 5 Years Whats Driving The Rally? (Stocktwits) +22.31%
Apr-06-26 01:50PM	Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners (PR Newswire) -5.56%
Mar-27-26 04:05PM	Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire) +9.71% -11.50%
Mar-04-26 08:30AM	Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis (GlobeNewswire)
Feb-26-26 08:00AM	Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire)
01:49AM	Loading…
Feb-19-26 01:49AM	What Pushed Entera Bio (ENTX) To Rally Nearly 16% After Hours (Benzinga)
Feb-11-26 09:00AM	Entera Bio Announces Open Market Purchases of Company Stock by Board Members (GlobeNewswire) +13.10%
Feb-09-26 08:50AM	Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones (GlobeNewswire) +27.88%
Feb-04-26 08:00AM	OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism (GlobeNewswire)
Jan-21-26 08:30AM	Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook (GlobeNewswire)
Dec-23-25 08:30AM	Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA's Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation (GlobeNewswire) -6.38%
Dec-22-25 08:30AM	Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program) (GlobeNewswire) +6.21%
Nov-18-25 08:00AM	Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference (GlobeNewswire)
Nov-14-25 04:05PM	Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Oct-23-25 08:50AM	Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women (GlobeNewswire) -6.96%
Oct-16-25 08:45AM	Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting (GlobeNewswire)
Sep-18-25 08:41AM	Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy (Zacks)
Aug-08-25 04:05PM	Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Jul-31-25 04:05PM	OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Jul-28-25 07:30AM	Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis (GlobeNewswire) +10.75%
08:00AM	Loading…
Jul-08-25 08:00AM	OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress (GlobeNewswire)
Jun-26-25 08:00AM	Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting (GlobeNewswire)
Jun-25-25 08:00AM	OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting (GlobeNewswire)
May-09-25 04:05PM	Entera Bio Announces First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Apr-15-25 08:30AM	Entera Bio's EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO (GlobeNewswire)
Mar-28-25 04:05PM	Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-18-25 11:37AM	Opko and Entera focus on oral care for obesity and metabolic disorders (Pharmaceutical Technology)
Mar-17-25 08:00AM	OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders (GlobeNewswire)
Feb-24-25 08:30AM	Entera Bio to Participate in Upcoming Events (GlobeNewswire)
Feb-19-25 08:00AM	EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (GlobeNewswire)
Jan-27-25 08:00AM	Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Nov-08-24 05:15PM	Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Sep-25-24 08:30AM	Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders (GlobeNewswire)
Sep-18-24 09:40AM	Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-02-24 09:40AM	Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-20-24 08:00AM	Entera Bio to Participate in Upcoming Investor and Scientific Conferences (GlobeNewswire)
Aug-15-24 12:00PM	All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy (Zacks)
Aug-09-24 04:05PM	Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-01-24 08:30AM	Entera's EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - Key SABRE Update Also Expected (GlobeNewswire)
Jul-23-24 06:28AM	3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years (InvestorPlace)
Jul-08-24 03:53PM	3 Meme Stocks That Can Surge by 200% Before 2025 (InvestorPlace) +5.99%
Jul-02-24 05:05PM	3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns (InvestorPlace)
Jun-25-24 04:37PM	3 Meme Stocks to Buy on the Dip: June 2024 (InvestorPlace) -9.22%
Jun-20-24 12:38PM	7 Penny Stocks to Turn $3 Into $1 Million Within 36 Months (InvestorPlace)
06:47AM	Rags to Riches: 3 Penny Stocks That Could Make Early Investors Rich (InvestorPlace)
06:47AM	Rag to Riches: 3 Penny Stocks That Could Make Early Investors Rich (InvestorPlace)
Jun-17-24 01:00PM	3 Penny Stocks to Turn $50,000 Into $1 Million: June 2024 (InvestorPlace)
Jun-10-24 07:22PM	Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 (InvestorPlace)
Jun-07-24 07:30AM	Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar (InvestorPlace)
Jun-03-24 09:40AM	Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year? (Zacks)
08:00AM	Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024 (GlobeNewswire)
May-23-24 06:45AM	The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom (InvestorPlace)
May-16-24 09:40AM	Are Medical Stocks Lagging Entera Bio (ENTX) This Year? (Zacks)
May-15-24 08:00AM	Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member (GlobeNewswire)
May-13-24 07:00AM	Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024 (GlobeNewswire)
May-10-24 08:53PM	ENTX Stock Earnings: Entera Bio Beats EPS for Q1 2024 (InvestorPlace)
04:10PM	Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-26-24 06:00PM	Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
Apr-18-24 06:15PM	Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today (Zacks) -11.16%
Apr-15-24 03:43PM	Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024? (InvestorPlace) -15.44%
Apr-12-24 09:40AM	Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? (Zacks) +12.03%
Apr-09-24 09:09AM	Here's Why You Should Invest in Entera Bio (ENTX) Stock Now (Zacks) +15.38%
Apr-08-24 08:30AM	Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research (GlobeNewswire)
Mar-26-24 08:30AM	Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months (GlobeNewswire)
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Mar-20-24 08:00AM	Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome (GlobeNewswire) +7.79%
Mar-08-24 04:05PM	Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire) +5.04%
Mar-04-24 08:30AM	Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +19.44%
Jan-30-24 08:30AM	Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-03-24 08:00AM	Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule (GlobeNewswire)
Dec-26-23 08:00AM	Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025 (GlobeNewswire)
Nov-29-23 08:30AM	Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform (GlobeNewswire)
Nov-14-23 07:30AM	Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development (GlobeNewswire)
Nov-09-23 02:30PM	Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis (GlobeNewswire) +20.64%
Oct-16-23 08:00AM	Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting (GlobeNewswire)
Sep-13-23 01:18PM	OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations (Zacks)
Sep-12-23 08:30AM	Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes (GlobeNewswire)
Sep-05-23 08:00AM	Entera Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-16-23 08:30AM	Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting (GlobeNewswire) +5.02%
Aug-11-23 04:05PM	Entera Bio Announces Q2 2023 Financial Results and Corporate Updates (GlobeNewswire) -17.57%
Jun-07-23 07:30AM	Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors (GlobeNewswire)
May-07-23 08:10AM	Entera Bio First Quarter 2023 Earnings: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022) (Simply Wall St.)
May-05-23 05:15PM	Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.70% +7.30%
04:05PM	Entera Bio Announces Q1 2023 Financial Results and Corporate Updates (GlobeNewswire)
May-04-23 10:00AM	Will Entera Bio Ltd. (ENTX) Report Negative Q1 Earnings? What You Should Know (Zacks)
May-03-23 09:34AM	Enteras Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics (GlobeNewswire) +10.00%
Apr-26-23 08:30AM	Menopause Luminary, Dr. Steven R. Goldstein, Joins Enteras Clinical and Scientific Advisory Board (GlobeNewswire)
Apr-03-23 07:00AM	Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program (GlobeNewswire) -13.36%
Mar-31-23 05:15PM	Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Germano Geno J	Director	Mar 09 '26	Buy	1.30	20,000	26,000	40,000	Mar 11 08:30 AM
Ellis Sean	Director	Mar 05 '26	Buy	1.23	10,000	12,300	188,098	Mar 09 08:30 AM
Rubin Steven D	Director	Feb 12 '26	Buy	1.49	5,000	7,450	15,000	Feb 17 08:30 AM
Rubin Steven D	Director	Feb 09 '26	Buy	1.20	10,000	12,000	10,000	Feb 11 08:44 AM
Ellis Sean	Director	Feb 09 '26	Buy	1.24	18,000	22,320	178,098	Feb 11 08:42 AM
Toledano Miranda Jayne	Chief Executive Officer	Dec 29 '25	Buy	1.81	11,000	19,912	426,575	Dec 30 06:01 AM

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH(1-34), GLP-1 and GLP-2. The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

CEO & DirectorMs. Miranda J. Toledano M.B.A.

Ph.D.Dr. Hillel Galitzer M.B.A.

Chief of Research & DevelopmentDr. Gregory Burshtein Ph.D.

Chief Financial OfficerMs. Dana Yaacov-Garbeli CPA

Chief Clinical AdvisorDr. Rachel B. Wagman

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENTX

Entera Bio Ltd

Upgrade your Finviz experience